SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented new findings that suggest APOPTONE™ (HE3235) is inhibiting in preclinical models of castration-resistant prostate cancer, the ability of tumors to synthesize the hormones necessary for their survival, as well as significantly down regulating the androgen receptor. Recent reports from the scientific literature indicate that androgen receptor signaling is active in all stages of prostate cancer, including late stage castration-resistant prostate cancer, and that castration-resistant prostate cancer may be driven by the intratumoral production of androgens. The Company’s new findings were reported this week at the 13th International Congress on Hormonal Steroids and Hormones & Cancer being held in Quebec City, Canada, September 27th – 30th. Dr. Richard Trauger, Director of Infectious Disease and Cancer at Hollis-Eden Pharmaceuticals, presented the data, from work performed by Dr. Eva Corey, Research Associate Professor, Department of Urology, at the University of Washington.
